Large Hedge Fund Reduces Stake in Immunology Drug Stocks to 20%

BVF Partners L.P. and its affiliated funds, the largest shareholders of MoonLake Immunotherapeutics (MLTX), sold a portion of their stake on Nasdaq on March 31. In an amended Schedule 13D filed on April 2, they disclosed that their Class A common stock ownership had fallen to approximately 22.3%.

BVF sold its shares at $16.79 apiece (about KRW 22,000), and in the filing stated it would continue to focus on investment asset management and joint voting rights, without indicating any plans for board participation or other shareholder activism.

According to a Form 4 filed the same day, aside from on-market sales, the only changes were a reconfirmation of the remaining shares held by BVF-affiliated funds and the existing stock options indirectly held under an economic agreement with independent director Spike Roy. No new option grants or exercises were reported.

In January, during a Type B meeting with the U.S. FDA, the company received positive feedback on the biologics license application pathway for sonelokimab—its candidate for treating the severe skin disease hidradenitis suppurativa. Based on this feedback, indicating that no additional large-scale Phase 3 trial may be required, MoonLake is refining its regulatory strategy. (ir.moonlaketx.com)

At the end of March, long-term data from Week 40 of the VELA-1 and VELA-2 Phase 3 trials showed sustained and enhanced efficacy across several measures, including the high-intensity response indicator HiSCR75. This has led some analysts to reaffirm their investment ratings and price targets, reflecting the increased likelihood of regulatory approval. (simplywall.st)

Headquartered in Zug, Switzerland, MoonLake Immunotherapeutics is a clinical-stage biotech focused on developing sonelokimab—a nanobody that simultaneously blocks interleukin-17A and ‑17F—for chronic inflammatory diseases such as hidradenitis suppurativa and psoriatic arthritis. (ir.moonlaketx.com)

The systemic autoimmune and inflammatory disease therapy market is dominated by biologics from major pharmaceutical companies like Novartis, Merck, and Eli Lilly. In this landscape, the clinical success of small and mid-size biotechs relying on a single pipeline asset remains a key determinant of their valuation and potential for mergers and acquisitions. (investing.com)